Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI

Trial Profile

Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Fluoxetine (Primary)
  • Indications Respiration disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 09 Feb 2017 Planned number of patients changed from 80 to 100.
    • 31 Jan 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top